Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Orders New Tests on Bird Flu Drug (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japan's Health Ministry has advised Roche and Chugai Pharmaceutical to investigate whether there is a link between the avian flu drug Tamiflu and delusional behavior. The companies, which partner in marketing Tamiflu in Japan, will begin clinical trials with between 12 and 30 human subjects, and also toxicity studies, to investigate this. Chugai officials say research results should be available at the end of 2007, and Roche says no evidence exists establishing a link between Tamiflu and delusion. Since 2001 when Tamiflu began to sell in Japan, over 1,300 people have demonstrated neuropsychiatric symptoms, and 71 people died while taking it. (Click here for more

You may also be interested in...



FDA To Periodically Publish List Of NOAs Due To COVID-19, But No Impact On EUA Sponsors

Due to strained resources and the slew of emergency use authorizations being requested by sponsors because of the COVID-19 crisis, the agency will now periodically publish Notices of Availabilities in the Federal Register instead of publishing immediately as the EUAs are handed out. However, companies will still get their NOA letters and can start marketing their products, and the agency will post the announcements sooner on its website.

Bigfoot Biomedical Closes $55M Series C Financing, Plans FDA Filing For Diabetes System

Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.

Warning Letter Close-Outs – May 2020

The US FDA released three device-related close-out letters in May.

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel